Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Switch Clear all
Completed Phase 1 Interventional

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

NCT02715531
View directory record Official record
Conditions
Solid Tumor
Interventions
5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

NCT00740051
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Linagliptin Placebo, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
15
States / cities
Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 17, 2026, 11:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pregnancy Exercise Mode Effect on Childhood Obesity

NCT04805502
View directory record Official record
Conditions
Pregnancy, Overweight and Obesity
Interventions
Exercise Modes
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

NCT02083965
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732
View directory record Official record
Conditions
HIV-1 Infection
Interventions
B/F/TAF, NRTIs, Third Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 17, 2026, 11:53 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 11:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia

NCT06763536
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Carbon Monoxide Measurement, Nicotine Lozenge, Oral Nicotine Pouch, Nicotine Patch, Survey Administration, Check-in Phone Calls
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 11:53 PM EDT
Recruiting Not applicable Interventional

Meditation for Older Adults With Chronic Low Back Pain

NCT06384001
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Active MBM, Sham MBM
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
50 Years to 89 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 17, 2026, 11:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Emergent Bilinguals: Child Language Proficiency and Language of Treatment

NCT06866223
View directory record Official record
Conditions
Developmental Language Disorder, Language Impairment
Interventions
Sentence recast
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
4 Years to 6 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Not applicable Interventional Results available

Optimize Low Back Pain

NCT03859713
View directory record Official record
Conditions
Low Back Pain, Chronic Pain
Interventions
Physical Therapy, Cognitive Behavioral Therapy, Mindfulness, Phase I Treatment, Phase II Switching
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 17, 2026, 11:53 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Sensorimotor Rhythm Brain-Computer Interface Switch to Operate Assistive Technology

NCT01117727
View directory record Official record
Conditions
Healthy
Interventions
Brain Computer Interface Switch
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 17, 2026, 11:53 PM EDT
Recruiting Phase 2 Interventional

Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

NCT07096362
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Gemcitabine, Nab Paclitaxel, Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
Drug · Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 11:53 PM EDT
Completed No phase listed Observational

MyTPill: A Novel Strategy to Monitor Antiretroviral Adherence Among HIV+ Prescription Opioid Users

NCT03978793
View directory record Official record
Conditions
HIV-positive Individuals
Interventions
MyTPill, a digital pill
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 17, 2026, 11:53 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Optimizing Outcomes for Young Autistic Children

NCT05926687
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Social Communication, Disruptive Behavior, Social Communication + Reduce Frequency, Social Communication + Add Tools, Disruptive Behavior + Reduce Frequency, Disruptive Behavior + Add Tools
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Months to 48 Months
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 1 Interventional

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

NCT05694364
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies
Interventions
Fludarabine, Cyclophosphamide, PRGN-3007
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 4 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

NCT03978832
View directory record Official record
Conditions
Schizophrenia
Interventions
PERSERIS, Risperidone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 17, 2026, 11:53 PM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

NCT02379390
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Muscle Shoals, Alabama • Anchorage, Alaska • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

NCT04223791
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
28
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

NCT02045797
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK2140944 Lyophile, GSK2140944 Capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Phoenix, Arizona • Anaheim, California • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

NCT02422797
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 17, 2026, 11:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Extinction Based Treatment for Nicotine Dependence

NCT00831155
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Nicotine Patches, Denicotinized Cigarettes
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 17, 2026, 11:53 PM EDT
Not listed Phase 4 Interventional

Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote

NCT00312676
View directory record Official record
Conditions
Epilepsy, Behavioral Disturbance
Interventions
Rapid versus slow conversion
Procedure
Lead sponsor
Veterans Affairs Medical Center, Miami
Federal
Eligibility
60 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2006 · Synced Oct 17, 2026, 11:53 PM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 17, 2026, 11:53 PM EDT